Soluble recombinant neutral endopeptidase (CD10) as a potential antiinflammatory agent.

Journal Article (Journal Article)

Several endogenous peptides, including bradykinin and substance P, have potent inflammatory effects in the joint. Levels of these peptides are regulated by plasma and cell-associated peptide degrading enzymes. One of these peptidases, neutral endopeptidase-24.11 (NEP-24.11), is expressed constitutively and in high density on human synovial cells and is presumed to play a critical role in local regulation of peptide levels in the joint. We examined the role of endogenous NEP-24.11 in regulating bradykinin-mediated effects in an articular model, and investigated the ability of soluble, recombinant human NEP-24.11 to augment the effects of the endogenous enzyme. Our studies demonstrate that endogenous synovial NEP-24.11 does not significantly modulate inflammatory peptide effects on cells when competing with colocalizing peptide receptors expressed in high density. Administration of excess, soluble recombinant NEP-24.11 can overcome this problem, however. Furthermore, the activity of the recombinant enzyme was not compromised in the presence of oxidants or inflammatory joint fluids. Recombinant NEP-24.11 holds promise as a novel therapeutic strategy for the treatment of inflammatory arthritis.

Full Text

Duke Authors

Cited Authors

  • Solan, NJ; Ward, PE; Sanders, SP; Towns, MC; Bathon, JM

Published Date

  • February 1998

Published In

Volume / Issue

  • 22 / 1

Start / End Page

  • 107 - 121

PubMed ID

  • 9484654

International Standard Serial Number (ISSN)

  • 0360-3997

Digital Object Identifier (DOI)

  • 10.1023/a:1022304025789


  • eng

Conference Location

  • United States